BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23719302)

  • 1. Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.
    Birger Y; Goldberg L; Chlon TM; Goldenson B; Muler I; Schiby G; Jacob-Hirsch J; Rechavi G; Crispino JD; Izraeli S
    Blood; 2013 Aug; 122(6):988-98. PubMed ID: 23719302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.
    Stankiewicz MJ; Crispino JD
    Blood; 2009 Apr; 113(14):3337-47. PubMed ID: 19168790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.
    Ng AP; Hu Y; Metcalf D; Hyland CD; Ierino H; Phipson B; Wu D; Baldwin TM; Kauppi M; Kiu H; Di Rago L; Hilton DJ; Smyth GK; Alexander WS
    PLoS Genet; 2015 May; 11(5):e1005211. PubMed ID: 25973911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
    Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
    PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The abundance of the short GATA1 isoform affects megakaryocyte differentiation and leukemic predisposition in mice.
    Ishihara D; Hasegawa A; Hirano I; Engel JD; Yamamoto M; Shimizu R
    Exp Hematol Oncol; 2024 Feb; 13(1):24. PubMed ID: 38409186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic and GATA1 sequencing analysis of hematopoiesis in fetuses with trisomy 21.
    Hoeller S; Bihl MP; Tzankov A; Chaffard R; Hirschmann P; Miny P; Kühne T; Bruder E
    Hum Pathol; 2014 May; 45(5):1003-9. PubMed ID: 24746204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient myeloproliferative disorder with partial trisomy 21.
    Takahashi T; Inoue A; Yoshimoto J; Kanamitsu K; Taki T; Imada M; Yamada M; Ninomiya S; Toki T; Terui K; Ito E; Shimada A
    Pediatr Blood Cancer; 2015 Nov; 62(11):2021-4. PubMed ID: 26138905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.
    Alford KA; Slender A; Vanes L; Li Z; Fisher EM; Nizetic D; Orkin SH; Roberts I; Tybulewicz VL
    Blood; 2010 Apr; 115(14):2928-37. PubMed ID: 20154221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus.
    Byrska-Bishop M; VanDorn D; Campbell AE; Betensky M; Arca PR; Yao Y; Gadue P; Costa FF; Nemiroff RL; Blobel GA; French DL; Hardison RC; Weiss MJ; Chou ST
    J Clin Invest; 2015 Mar; 125(3):993-1005. PubMed ID: 25621499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
    Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
    Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
    Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.
    Juban G; Sakakini N; Chagraoui H; Cruz Hernandez D; Cheng Q; Soady K; Stoilova B; Garnett C; Waithe D; Otto G; Doondeea J; Usukhbayar B; Karkoulia E; Alexiou M; Strouboulis J; Morrissey E; Roberts I; Porcher C; Vyas P
    Haematologica; 2021 Apr; 106(4):1106-1119. PubMed ID: 32527952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
    Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
    Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular insights into Down syndrome-associated leukemia.
    Vyas P; Crispino JD
    Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
    Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
    PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome.
    Ng AP; Hyland CD; Metcalf D; Carmichael CL; Loughran SJ; Di Rago L; Kile BT; Alexander WS
    Blood; 2010 May; 115(19):3966-9. PubMed ID: 20007548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GATA1s isoform is normally down-regulated during terminal haematopoietic differentiation and over-expression leads to failure to repress MYB, CCND2 and SKI during erythroid differentiation of K562 cells.
    Halsey C; Docherty M; McNeill M; Gilchrist D; Le Brocq M; Gibson B; Graham G
    J Hematol Oncol; 2012 Aug; 5():45. PubMed ID: 22853316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1 N terminus in erythropoiesis.
    Ling T; Birger Y; Stankiewicz MJ; Ben-Haim N; Kalisky T; Rein A; Kugler E; Chen W; Fu C; Zhang K; Patel H; Sikora JW; Goo YA; Kelleher N; Zou L; Izraeli S; Crispino JD
    Blood; 2019 Nov; 134(19):1619-1631. PubMed ID: 31409672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
    Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
    Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.